Clinical trials: Anal Cancer
Anal Cancer Squamous Cell
Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)
Phase II randomized study of the use of pre-and probiotics during the definitive treatment of chemotherapy-radiotherapy (Ch-RT) for patients with localized anal canal squamous cell cancer (ACSCC) with the objective of increasing…
- Trial name
- BISQUIT (NCT03870607)
- Testing
- prebiotics in combination with probiotics
- Where
- Brazil
- Volunteers
- 75 people
- Sponsor
- AC Camargo Cancer Center
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions.
- Trial name
- NCT04276935
- Testing
- Interview, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- AIDS Malignancy Consortium
Rectal Cancer, Low Anterior Resection Syndrome
Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer
This prospective, single-center, single-arm, open-label clinical study aims to evaluate whether autologous fecal microbiota transplantation can improve bowel and anal function after ileostomy reversal in patients with rectal…
- Conditions
- Rectal Cancer, Low Anterior Resection Syndrome, Fecal Incontinence, Diversion Colitis
- Trial name
- NCT07711509
- Testing
- Autologous Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking University People's Hospital
Anal Cancer
Individual Following in Anal Cancer With PET/CT
Anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. Incidence is less than 1/100 000 of the general population.
- Trial name
- IFACT (NCT02697084)
- Testing
- anal cancer
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Anal Cancer
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00423293
- Testing
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Where
- 172 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
AIDS-Related Anal Carcinoma, AIDS-Related Cervical Carcinoma
Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico
This clinical trial aims to find what different tests work best to find high-grade squamous intraepithelial lesions (HSIL) in the cervix or anus in patients living with human immunodeficiency virus (HIV).
- Conditions
- AIDS-Related Anal Carcinoma, AIDS-Related Cervical Carcinoma, High Grade Anal Intraepithelial Neoplasia, High Grade Cervical Intraepithelial Neoplasia
- Trial name
- CAMPO-101 (NCT05074264)
- Testing
- Biopsy, Biospecimen Collection - Anal, Biospecimen Collection - Cervical
- Where
- 4 sites in Mexico, Puerto Rico
- Volunteers
- 1,586 people
- Sponsor
- University of California, San Francisco
Anal Dysplasia
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
- Trial name
- SCAN-LITE (NCT06971276)
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
HIV Infections, Anal Cancer
Screening for HIV-Associated Anal Cancer
Cancer of the anus occurs at very high rates in young men with HIV and is caused by a virus called human papillomavirus (HPV). Anal cancer has increased during the HIV epidemic despite effective therapies for HIV.
- Conditions
- HIV Infections, Anal Cancer, Anal Dysplasia, Papillomavirus Infections
- Trial name
- TRACE (NCT00188292)
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancers, Lung and Esophagus Cancers
Adaptive Pet Study
The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment.
- Conditions
- Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
- Trial name
- NCT01908504
- Testing
- PET-CT
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Duke University
Anal Cancer, Colorectal Cancer
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
RATIONALE: Gathering information about patients' quality of life during radiation therapy for cancer may help doctors plan the best treatment.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00836992
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Mayo Clinic
Anus Neoplasms, Rectal Neoplasms
Alkagin Paste in the Prevention of Radiation Dermatitis
The purpose of this study is to determine whether Alkagin paste is effective at preventing radiodermatitis in patients receiving external beam radiation therapy to the perineal area.
- Conditions
- Anus Neoplasms, Rectal Neoplasms, Urogenital Neoplasms
- Trial name
- NCT01408407
- Testing
- Aveeno cream, Alkagin paste
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Diverting Ileostomy, Middle and Low Rectal Cancer
Diverting Ileostomy and Anal Functional Outcomes After Anus Preservation Surgery
Analyze the occurrence of complications, rectal function and quality of life after anus-preserving surgery for middle and low rectal cancer, so as to evaluate the role of protective ileostomy.
- Conditions
- Diverting Ileostomy, Middle and Low Rectal Cancer, Functional Outcome, Stoma Complications
- Trial name
- NCT04776421
- Testing
- Diverting ileostomy
- Volunteers
- 300 people
- Sponsor
- The First Hospital of Jilin University
Anal Canal Squamous Cell Carcinoma
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who…
- Trial name
- NCT04499352
- Testing
- BI 754091, BI 836880
- Where
- South Korea
- Sponsor
- Boehringer Ingelheim
HPV
Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study
Comunity health actions are set up in populations of women aged 30 to 65 in vulnerable situations living in the outlying areas of Reunion Island. The idea is to evaluate those action on health
- Trial name
- ALONDEPISTHPV (NCT07438080)
- Testing
- Public health workshop in community
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Anal High-Grade Squamous Intraepithelial Lesions
Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
The purpose of this study is to finalize development of a questionnaire that measures health-related symptoms and concerns for persons diagnosed with, and either treated or monitored for, anal pre-cancer lesions.
- Trial name
- NCT02836522
- Testing
- Assessment of Health-Related Quality
- Where
- 4 sites in United States
- Volunteers
- 406 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV Infections, Anus Neoplasms
A Study of Anal Cancer Development in HIV Infected People
The purpose of this study is to compare the development of abnormal cell growth or cancer in the anal region of individuals who are receiving one of two different anti-HIV treatment strategies.
- Trial name
- NCT00107679
- Where
- 13 sites in United States
- Volunteers
- 560 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Canal Carcinoma
Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma
Squamous cell carcinoma of the anal canal (SCCA) is a rare disease and mostly diagnosed at an early stage. After standard concurrent chemoradiation (CRT) with mitomycin (MMC) and 5-fluorouracil (5FU), the disease will recur in…
- Trial name
- Epitopes-HPV02 (NCT02402842)
- Testing
- Docetaxel, Cisplatin and 5-Fluorouracil
- Where
- 16 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Anal Cancer
Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?
Local excision for early rectal cancer has proven its feasibility and oncological safety. Indeed, lymph node invasion does not exceed 1% and 10% in pT1sm1 and pT1sm2 rectal carcinomas respectively.
- Trial name
- MUCEM (NCT02885142)
- Testing
- Local excision for early rectal cancer
- Where
- France
- Volunteers
- 368 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HPV-Related Anal Intraepithelial Neoplasia, AIN2/3
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
- Conditions
- HPV-Related Anal Intraepithelial Neoplasia, AIN2/3, Artesunate, Alternative Treatment
- Trial name
- ART-AIN (NCT03100045)
- Testing
- Artesunate Suppositories
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and…
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Trial name
- GOBLET (NCT07280377)
- Testing
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
- Where
- 15 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Oncolytics Biotech